Regulus Therapeutics, Inc.

Regulus Therapeutics, Inc.

Regulus Therapeutics, Inc.

Overview
Date Founded

2007

Headquarters

10628 Science Center Drive, Suite 225, San Diego, CA, 92121, USA

Type of Company

Public

Employees (Worldwide)

21

Industries

Pharmaceuticals
Hospitals & Patient Services
Biotechnology

Company Description

Regulus Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in September 2007 and is headquartered in San Diego, CA.

Contact Data
Trying to get in touch with decision makers at Regulus Therapeutics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

Chief Financial Officer

Secretary, Senior Vice President & General Counsel

Chief Scientific Officer

Senior Vice President, Human Capital

Vice President, Pharmaceutical Development

Vice President, Pharmaceutical Development

Leader

Controller

Director

Paths to Regulus Therapeutics, Inc.
Potential Connections via
Relationship Science
You
Regulus Therapeutics, Inc.
Recent Transactions
Details Hidden

Regulus Therapeutics, Inc. raised money in a private placement transaction

Details Hidden

Regulus Therapeutics, Inc. issued USD Common Stock

Details Hidden

Regulus Therapeutics, Inc. issued USD Common Stock

Insider Transactions
Details Hidden
Details Hidden
Transaction Advisors
Underwriter

Advised onRegulus Therapeutics, Inc. issued USD Common Stock

Underwriter

Advised onRegulus Therapeutics, Inc. issued USD Common Stock

Underwriter

Advised onRegulus Therapeutics, Inc. issued USD Common Stock

Legal Advisor

Advised onRegulus Therapeutics, Inc. issued USD Common Stock

Managing Director

Advised onRegulus Therapeutics, Inc. issued USD Common Stock

Professional

Advised onRegulus Therapeutics, Inc. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Partner, San Diego at Cooley LLP

Advisor

President Emeritus at California Institute of Technology

Advisor

Co-Founder at Alnylam Pharmaceuticals, Inc.

Clients

Sanofi, a diversified global healthcare leader, discovers, develops, and distributes therapeutic solutions to improve the lives of everyone. We work to prevent and treat the diseases that we know of today, as well as those we may face tomorrow. With nearly 100,000 dedicated professionals in more than 100 countries, Sanofi is devoted to advancing healthcare around the world. Sanofi US, with headquarters in Bridgewater, New Jersey, along with our vaccines division, Sanofi Pasteur, employs more than 11,400 professionals throughout the country. At Sanofi, we work for what really matters: health

Key Stats and Financials As of 2019
Market Capitalization
$18.6M
Total Enterprise Value
$-3.43M
Earnings Per Share
$-1.08
Revenue
$6.83M
Net Profit
$-18.6M
EBITDA
$-15.9M
EBITDAMargin
-232.77%
Five Year Compounded Annual Growth Rate Of Revenue
-2.28%
Three Year Compounded Annual Growth Rate Of Revenue
78.86%
Debt TEV
-4.47x
TEVNet Income
0.18x
Enterprise Value / Sales
-0.5x
Total Equity
$20M
Total Debt
$15.3M
Non-Profit Donations & Grants
$25K - $50K
2012
$25K - $50K
2011
Investors
Details Hidden

Sanofi-Aventis U.S. LLC engages in the provision of pharmaceutical products. It discovers, develops, produces and markets innovative therapies. The firm extensive research and development efforts are focused on health care challenges in cardiology, oncology and internal medicine, as well as metabolic diseases, central nervous system disorders, ophthalmology and vaccines. The company is headquartered in Bridgewater, NJ.

Suppliers
Alnylam Pharmaceuticals, Inc. Medical Support Services | Cambridge, Massachusetts

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Ionis Pharmaceuticals, Inc. Medical Support Services | Carlsbad, California

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.

Swiss Federal Institute of Technology Computer Software | Zurich, Switzerland

École Polytechnique Fédérale de Lausanne

Competitors
Roche Holding AG Pharmaceuticals - Basel, Switzerland

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Regulus Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Regulus Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Regulus Therapeutics, Inc..